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Resumo
Apesar de uma melhoria significativa dos cuidados prestados no âmbito da doença coronária aguda, a mortalidade 
e morbilidade associadas a esta última continuam  significativas. Uma das explicações para esta ainda elevada mortalidade 
reside no facto de que a própria reperfusão coronária pode paradoxalmente provocar lesão miocárdica adicional, através da 
denominada lesão de isquemia-reperfusão, comprometendo assim, pelo menos parcialmente, o efeito benéfico da reperfusão 
miocárdica.
Ao longo das últimas duas décadas, várias intervenções farmacológicas (como o uso de antioxidantes, anti-inflamató-
rios, magnésio, glicose/insulina/potássio ou a rápida normalização do pH) foram estudadas com o intuito de prevenir a lesão de 
isquemia-reperfusão. Apesar dos resultados promissores obtidos com a experimentação animal, as tentativas de transposição 
desses resultados para o ser humano e consequentemente para a prática clínica têm sido desapontadoras.
Por outro lado, o condicionamento isquémico cardíaco é uma intervenção que tem produzido resultados positivos. De 
forma genérica, o conceito de “condicionamento isquémico” remete para a protecção induzida por curtos períodos de isque-
mia intercalados por períodos de reperfusão, previamente a um evento isquémico major. Os estímulos isquémicos podem ser 
aplicados antes (pré-condicionamento), durante (per-condicionamento) ou após (pós-condicionamento) o evento isquémico.
Uma descoberta importante no âmbito da investigação sobre condicionamento isquémico cardíaco, foi a de que a 
protecção podia ser induzida à distância, introduzindo o conceito de condicionamento isquémico remoto.
 No presente trabalho, propusemo-nos rever os mecanismos subjacentes ao condicionamento isquémico cardíaco 
remoto e abordar as suas aplicações clínicas, considerando mais especificamente o pré- e o per-condicionamento.
Summary
Remote cardiac ischemic conditioning: Underlying mechanisms and clinical 
applications
Despite a significant improvement in the care of acute coronary disease, mortality and morbidity remain important. One 
explanation for this lies in the fact that the very coronary reperfusion may paradoxically result in additional myocardial injury, 
through the so-called ischemia-reperfusion injury, partially mitigating the beneficial effects of myocardial reperfusion.
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Over the past two decades, numerous pharmacological interventions (such as the use of antioxidants, anti-inflammatory, 
magnesium, glucose/insulin/potassium, rapid normalization of pH) were studied in order to prevent ischemia-reperfusion injury. 
Despite the promising results obtained in animal experiments, attempts to transpose these results to humans, and consequently 
to clinical practice, have been disappointing.
On the other hand, cardiac ischemic conditioning is an intervention that has produced positive results. Ischemic condi-
tioning refers to the protection induced by short periods of ischemia followed by reperfusion, prior to a major ischemic event. 
Ischemic stimulus can be applied before (pre-conditioning), during (per-conditioning) or after (post-conditioning) the major 
ischemic event.
An important finding regarding cardiac ischemic conditioning, was that protection could be induced remotely, introdu-
cing the concept of remote ischemic conditioning.
In this paper, we proposed to review the mechanisms underlying remote ischemic cardiac conditioning and the possible 
clinical applications, considering more specifically pre and per-conditioning
INTRODUCTION
Coronary heart disease is one of the leading causes 
of mortality worldwide, accounting for more than 7 million 
deaths per year (about 12.8% of all deaths)1. It is estimated 
that in Europe every sixth man and every seventh woman will 
die of acute myocardial infarction (AMI)2.
However, recent studies and registries have showed 
a reduction in AMI mortality following the increased use of 
reperfusion therapy (mainly with percutaneous coronary 
intervention), newer antithrombotic therapies, and adhe-
rence to secondary prevention measures (pharmacological 
treatment and changes in lifestyle)3-6. In the context of AMI 
with ST segment elevation, rapid restoration of coronary 
flow is actually the most effective strategy for reducing the 
infarct size and thus improving prognosis associated with 
AMI.
Thus, despite a significant improvement in the care 
of acute coronary disease, mortality and morbidity associa-
ted with the latter remain high.
One of the reasons for a mortality rate still so high 
is that reperfusion itself can paradoxically cause additional 
myocardial injury, through the so-called ischemia-reperfusion 
injury (or reperfusion injury), reducing the beneficial effects of 
myocardial reperfusion7-9. Ischemia-reperfusion injury (IRI) has 
classically been described as causing four main types of car-
diac dysfunction: myocardial stunning, the phenomenon of 
“no-reflow”, reperfusion arrhythmia and myocardial necrosis 
(called “lethal reperfusion injury”)9-12. IRI may account for up 
to 40 - 50% of the final infarct size, thereby contributing to 
an increased mortality and progression to heart failure (Fig. 
1)9. Several factors have been suggested as contributing to IRI: 
oxidative stress, changes in pH, calcium overload and acute 
inflammatory response. These events favour the opening of 
Figure 1 Schematic representation of the contribution of ischemia-reperfusion injury to the final size of myocardial infarction.
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the mitochondrial permeability transition pore (mPTP). The 
mPTP is a non-specific channel located in the inner membrane 
of the mitochondria whose opening leads ultimately to cell 
lysis8, 9, 13-16. The mPTP is thus a critical determinant of IRI.
Over the past three decades, several pharmacological 
interventions (use of antioxidants, anti-inflammatory agents, 
magnesium, glucose/insulin/potassium or rapid normalization 
of pH) were studied in order to prevent IRI. Despite promi-
sing results in animal experiments, attempts to translate those 
results into humans have been largely disappointing9,17,18.
On the opposite, cardiac ischemic conditioning is an 
intervention that has produced positive results, both in ani-
mal experiments and in human clinical trials17-27.
The concept of “ischemic conditioning” refers to the 
protection induced by short cycles of ischemia and reperfu-
sion prior to a major ischemic event. Various studies have 
shown that ischemic conditioning is ubiquitous and can be 
applied in all organs.
Murry et al. first described cardiac ischemic conditio-
ning in a canine model in 198628-29. These authors observed 
that the application of four 5-minutes cycles of myocardial 
ischemia (by occlusion of a coronary artery) alternating with 
5-minutes of reperfusion could protect the myocardium 
against a longer period of ischemia. In subsequent years, 
ischemic conditioning was the subject of intense inves-
tigation, both in the description of the underlying cellu-
lar mechanisms and the assessment of its effectiveness in 
various clinical settings17-27.
Due to the extensive research conducted in the last 
25 years, we now know that stimuli may be applied before 
ischemia (preconditioning - as originally described by Murry 
et al.), during (per-conditioning) or after (post-conditioning) 
the major ischemic event, thereby allowing three windows 
for the application of this therapeutic intervention.
An important discovery about cardiac conditioning 
was the existence of two windows of cardioprotection. After 
the initial ischemic stimulus, the protection induced imme-
diately, called “classic ischemic preconditioning”, extends 
over a maximum period of about 1 to 2 hours. Notably, 12 
to 24 hours after the initial ischemic stimulus, a second win-
dow appears, lasting for 48 to 72 hours, although resulting 
in a lesser amount of protection30.
Another remarkable finding about cardiac ischemic 
conditioning was that cardioprotection could be induced at 
a distance, introducing the concept of remote cardiac ische-
mic conditioning.
DEFINITION
Remote cardiac ischemic conditioning (RCIC) descri-
bes the cardioprotection induced by short cycles of ischemia 
and reperfusion applied to a distant organ before, during or 
even after a prolonged period of myocardial ischemia.
Przyklenk et al. first described the concept of RCIC (as 
preconditioning) in 199331. These authors demonstrated, in 
a canine model, that the application of transient ischemia to 
the circumflex coronary artery territory lessened the effects 
of a potentially lethal ischemia subsequently applied to the 
territory supplied by the anterior descending coronary artery.
Later, in 2002, Kharbanda et al. demonstrated that 
RCIC could be reproduced non-invasively by applying short 
periods of ischemia and reperfusion in the forearm, using a 
blood pressure cuff32. Since then, several studies have highli-
ghted the benefits of RCIC in different clinical circumstan-
ces25-27.
MECHANISMS
Although the mechanisms underlying the immediate 
cardioprotection of RCIC are not fully understood, studies 
have shown that some of the signalling pathways activated 
in cardiomyocytes preconditioned at a distance appear to be 
similar to the ones recruited in preconditioning and post-
-conditioning applied directly to the heart33-36.
However, it is the mechanism linking the remote 
organ to the heart that is less clear and which constitutes the 
main difference between the direct and the remote ischemic 
conditioning35.
1. Communication between the remote organ and 
the heart
Three main hypotheses, each one favouring a diffe-
rent pathway, were proposed to explain the transmission of 
a protective signal from the remote organ to the heart.
a. Humoral pathway
The observation that a period of reperfusion of the 
organ submitted to briefs periods of ischemia was neces-
sary for remote cardioprotection to occur, soon raised the 
suspicion that reperfusion was required to carry a substance 
previously produced by ischemic preconditioning37-38. Later, 
several studies added arguments to this hypothesis. One 
study revealed the occurrence of cardioprotection in a rab-
bit receiving blood from another rabbit previously submit-
ted to local and remote cardiac preconditioning39. Another 
study showed that a pig, receiving a denervated heart and 
subsequently subjected to ischemia of a limb, continued to 
benefit from cardioprotection, reinforcing the hypothesis of 
a humoral factor mediating the cardioprotection40.
Some of the substances identified as possible humo-
ral factor are opioids, endocannabinoids and adenosine41-44.
b. Neuronal pathway
When considering the neuronal pathway hypothe-
sis, it was proposed that afferent nerve fibres of the remote 
organ were activated by endogenous substances produced 
by the ischemic stimulus, with subsequent activation of effe-
rent nerve fibres in the heart. The substances most often 
involved in the activation of afferent nerve fibres are adeno-
sine, bradykinin and the neurotransmitter CGRP (“calcitonin 
gene-related peptide”)45-48.
Several studies have pointed the existence of a neu-
ronal pathway for the transmission of the cardioprotective 
signal and assessed possible candidates for the initial acti-
vation of the afferent nerve fibres. In general, the various 
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studies followed a similar methodology: the role of the ner-
vous system in the signal transmission of cardioprotection 
was shown by demonstrating its inhibition following the 
destruction of afferent nerve fibres in the remote organ sub-
mitted to the initial ischemic stimulus45-48.
c. Systemic pathway
RCIC has been shown to suppress the inflammatory 
response and induce a favourable profile of gene transcrip-
tion in the myocardium, promoting anti-inflammatory and 
anti-apoptotic responses49,50. The understanding of the exact 
contribution of such responses in the cardioprotection indu-
ced by RCIC requires further investigation.
It should be noted that the pathways described 
above are likely not mutually exclusive but rather interact 
with each other.
2. Mechanisms involved in myocardial cardioprotec-
tion elicited by remote conditioning
After the cardioprotective signal has been trans-
mitted from the remote organ to the heart, intracellular 
mechanisms of signal transduction are recruited to mediate 
Figure 2 Mechanisms underlying cardiac remote ischemic conditioning.CGRP: calcitonin gene-related peptide; Erk 1/2: extracellular signal-regulated kinases; JNK: Jun N-terminal kinase; KATP channel: ATP-
dependent mitochondrial potassium channel; MAPK: mitogen-activated protein kinases; mPTP: mitochondrial permeability transition pore; 
NO: nitric oxide; RISK: reperfusion injury salvage kinase; SAFE: survivor activating factor enhancement; “+”: stimulation / activation.
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cardioprotection. At this point, the mechanisms are similar 
to the ones underlying ischemic pre and post-conditioning 
applied directly to the heart34-36, 51-52.
The first step is the activation of G protein coupled 
receptors by ligands as adenosine, bradykinin, angiotensin 
I, opioids and endocannabinoids41,44,45,53. The activation of 
these receptors will in turn lead to the activation of intra-
cellular protein kinases such as protein kinase G, protein 
kinase C (especially its isoform ), protein kinases Akt and 
Erk 1/2 (kinases of the protective RISK pathway - “reperfu-
sion injury salvage kinase”) or generation of intracellular sig-
nalling molecules such as nitric oxide (NO) or reactive oxygen 
species45,54-57. Another pathway that may also mediate car-
dioprotection in RCIC, as in classical pre-conditioning, is the 
SAFE pathway (“survivor activating factor enhancement”) 
that involves the activation of STAT1/3 (“signal transducer 
and activator of transcription”) by TNF, conferring cardio-
protection through induction of anti-apoptotic genes and 
inhibition of pro-apoptotic ones58.
The final target of the various intracellular mecha-
nisms seems to be the mitochondria via the activation of 
the mitochondrial ATP-dependent potassium channel (KATP 
channel) and, ultimately, the inhibition of the opening of the 
mitochondrial permeability transition pore (mPTP)51,59-62. As 
mentioned above, the mPTP is a non-specific channel loca-
ted in the inner membrane of the mitochondria. Its opening 
leads to an equilibrium of H+ ions on each side of the mem-
brane with the consequent loss of the membrane potential 
necessary for ATP production. The mPTP also allows the 
entry of water into the mitochondria, causing its dilation 
and ultimately cell lysis. The opening of the mPTP is favoured 
by increased intracellular concentration of Ca2+, inorganic 
phosphate and reactive oxygen species, which occurs after 
reperfusion9. The various intracellular signalling pathways 
mentioned previously inhibit mPTP opening, preventing the 
cascade of events leading to the death of the myocyte51,59-61.
3. DELAYED CARDIOPROTECTION OR SECOND WIN-
DOW OF PROTECTION
As in cardiac conditioning induced locally, RCIC 
seems to induce two windows of protection, one immediate 
and one delayed33,62.
The mechanisms underlying the delayed response are 
very similar to those described for the immediate response: 
communication between the remote organ and the heart, 
triggers recruiting mediators which in turn lead to the acti-
vation of the effector of cardioprotection (most probably the 
mPTP)62.
The main difference between the delayed and imme-
diate responses lies in the recruitment of early mediators 
(protein kinase C, protein tyrosine kinase, MEK 1/2-Erk 
1/2,...), which activate transcription factors (STAT 1/3, NFB 
(“nuclear factor kappa-light-chain enhancer of activated 
B-cells”), AP-1 (“activator-protein-1”), Nrf2 (“nuclear factor-
-like 2 ‘),...). These transcription factors induce the synthesis 
of distal mediators 12 to 24 hours later (inducible NO syn-
thase, heat shock proteins, cyclooxygenase 2). These media-
tors finally recruit the final effectors of cardioprotection 
(mitochondrial KATP channel and mPTP)62.
The intermediate steps described above explain the 
observed delay of 12 to 24 hours until the beginning of the 
second window of protection.
The proposed mechanisms underlying RCIC are sum-
marized in Fig. 2.
CLINICAL APPLICATIONS
When we considered the ischemic preconditioning, 
the need to apply the stimulus prior to the ischemic heart 
injury limits its application to situations in which myocardial 
injury is predictable. Thus, the ideal context for the applica-
tion of ischemic preconditioning of the heart is elective inter-
ventions associated with myocardial injury such as cardiac 
surgery and percutaneous coronary angioplasty.
On the other hand, ischemic per-conditioning begun 
to be studied in the last 5 years, as an adjunct to angioplasty 
in the context of AMI with ST segment elevation.
1. Cardiac surgery
Perioperative myocardial injury after cardiac surgery 
(evidenced by the elevation of biomarkers of myocardial 
necrosis such as troponin I or T) is associated with worse 
prognosis. As a result, the prevention of the former is of 
great importance63-66.
Cardiac surgery for the correction of congenital 
defects in children was the first clinical setting in which 
remote cardiac ischemic pre-conditioning (RCIPreC) has been 
studied23. In the study by Cheung and co-workers, a protocol 
of remote ischemic preconditioning (four 5-minute cycles of 
inflation and deflation of a blood pressure cuff applied to 
the thigh) allowed the reduction of perioperative myocardial 
injury (demonstrated by the lower elevation of troponin I), 
need for inotropic support and airway resistance23.
In the context of coronary artery bypass surgery 
(CABG) in adults, Hausenloy et al. were the first to demons-
trate that RCIPreC (induced by three 5-minute cycles of infla-
tion and deflation of a blood pressure cuff applied to the 
arm) could lead to a reduction of perioperative myocardial 
injury24. Subsequently, several studies have confirmed the 
cardioprotective effect of RCIPreC in CABG surgery67-68.
However, one of the biggest studies performed after-
ward in the setting of CABG showed negative results, failing 
to demonstrate beneficial effects of a remote ischemic pre-
conditioning protocol (three 5-minute cycles of inflation and 
deflation of a blood pressure cuff applied to the arm). Some 
hypotheses have been evoked to explain the negative results 
of this study: the inclusion of patients with recurrent angina 
(unintentionally preconditioned), nitrate use, the anesthetic 
protocol and inefficiency of remote ischemic preconditio-
ning protocol69.
Two large trials (ERICCA and RIPHeart), with samples 
large enough to demonstrate possible benefits of RCIPreC 
in regard to hard clinical events, are currently under recruit-
ment. These studies will bring more definitive answers regar-
ding the clinical utility of RCIPreC in the setting of CABG.
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2. Elective percutaneous coronary angioplasty
As shown for cardiac surgery, the occurrence of myo-
cardial injury in the setting of elective percutaneous coro-
nary intervention (PCI) is associated with worse prognosis, 
making necessary the utilization of effective strategies for its 
prevention70-73.
The first clinical study evaluating RCIPreC for elective 
PCI did not show any benefit, possibly due to an inadequate 
remote ischemic conditioning protocol74. However, in a sub-
sequent study conducted by Hoole et al. (CRISP trial), a pro-
tocol of remote ischemic preconditioning (three 5-minute 
cycles of inflation and deflation of a blood pressure cuff 
applied to the arm) resulted in a lower troponin T elevation 
after the procedure25. Interestingly, the same authors did not 
demonstrate benefits of RCIPreC in reducing myocardial dys-
function in patients with coronary heart disease submitted 
to dobutamine stress echocardiography75.
We are currently missing large-scale trials to evaluate 
a possible impact on the prevention of adverse clinical events.
3. Acute myocardial infarction with ST-segment ele-
vation
Despite intense investigation on cardiac ischemic 
conditioning for over two decades, only recently protocols 
of remote ischemic conditioning have been tested in the set-
ting of AMI with ST segment elevation26-27.
In 2010, Rentoukas et al. were the first to present the 
results of a randomized trial testing the effect of a protocol 
of remote cardiac ischemic per-conditioning (RCIPerC), with 
or without morphine, in the setting of AMI with ST-segment 
elevation. In this study, 96 patients were randomized into 
3 groups: RCIPerC (three cycles of 4-minute inflations and 
deflations of a blood pressure cuff placed on the upper arm; 
inflation to 20 mmHg above systolic pressure and deflation 
to 0 mmHg), RCIPer with morphine (administered prior 
to per-conditioning) or control treatment (three cycles of 
4-minute inflation to 20 mmHg below diastolic blood pres-
sure of a blood pressure cuff placed on the upper arm and 
deflation to 0 mmHg). Overall, a complete resolution of ST 
elevation was achieved more often in patients receiving any 
form of RCIPerC. The group that received RCIPerC with mor-
phine had a greater reduction in ST elevation and lowest 
elevation of troponin I in relation to the control group while 
the patients undergoing RCIPerC alone had a non significant 
trend for greater reduction of ST elevation and lower eleva-
tion of troponin I26.
In 2010, Botker et al. published the results of the 
largest randomized study conducted so far to evaluate the 
effects of RCIPerC in the setting of AMI with ST-segment 
elevation. In this study, 333 patients were randomized to 
RCIPerC (four 5-minute cycles of inflation to 200 mmHg and 
deflation to 0 mmHg of a blood pressure cuff applied to 
the arm) or control treatment (deflated cuff placed on the 
arm). Although only 142 of the 333 patients initially rando-
mized were analysed, a higher rate of myocardial salvage 
was observed among patients undergoing RCIPerC (0.75 vs. 
0.55, p = 0.0333). The authors also showed that the bene-
ficial effects of RCIPerC were more pronounced in patients 
presenting with more extensive EAM, particularly those rela-
ted to the occlusion of the left anterior descending.
Studies of larger scale are needed for assessing the 
effect of RCIPerC on the incidence of more relevant clinical 
adverse events.
CONCLUSION
The mortality associated with coronary heart disease 
has been declining in recent years as a result of the greater 
use of revascularization (both percutaneous and surgical) 
and the improvement of antithrombotic treatment. Howe-
ver, the in-hospital mortality recorded in European countries 
remains high, ranging between 6 and 14%2. One factor that 
may contribute to this still significant mortality is the IRI. The 
IRI may contribute to up to 40 to 50% of the final infarct 
size, thereby facilitating the development of heart failure 
with the significant mortality and morbidity associated to it9.
Remote ischemic conditioning is a safe, non-invasive 
and very low cost intervention with the potential to reduce 
the morbidity and mortality associated with coronary heart 
disease. Until now, extensive investigation has been conduc-
ted with positive results. In the past 5 years, several studies 
have evaluated the potential beneficial effects of RCIC in 
human, once again with encouraging results. However, we 
are lacking large-scale studies to verify the clinical impact of 
RCIC, namely for the reduction of clinically relevant adverse 
events. These studies may confirm RCIC as a clinically useful 
tool or confine it to laboratory studies.
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